Skip to content

Glutamine and Intestinal Protein Metabolism

Comparative Effects of Glutamine and Glucose on Intestinal Protein Metabolism in Healthy Humans

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00213551
Enrollment
30
Registered
2005-09-21
Start date
2004-04-30
Completion date
2008-06-30
Last updated
2013-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

Gut barrier plays a major role in defence of the organism. During catabolic states, like major surgery or inflammation, gut barrier could be altered. It has been reported that preoperative nutritional support may have beneficial effects on clinical outcome in patients with surgery on gastrointestinal tract. Glutamine, which is a conditionally essential amino, have been reported to modulate inflammatory, antioxidant responses and protein metabolism in intestine. In addition, glutamine supply improves clinical outcome in critically ill patients. Antioxidant micronutrients may also have some beneficial effects in intestine by improving antioxidant response and might also regulate protein expression. Nevertheless, effects of glutamine combined to antioxidant micronutrients have not been evaluated. Thus, the aim of this study will be to assess the influence of glutamine and glutamine-antioxidant micronutrients-containing solutions on intestinal response in humans.

Interventions

DRUGGlutamine
DRUGGlucose
DRUGglutamine-antioxidants containing solution

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers, male and female, aged between 18 and 50 years, negatives for HIV1, 2 and for HVC and HVB * BMI between 20 and 24 kg/m², * giving their written informed consent * no-smokers * no allergic and digestive antecedents

Exclusion criteria

* smokers * Allergic and digestive antecedents, * pregnancy

Design outcomes

Primary

MeasureTime frame
Impact on protein synthesis rate and proteolytic activities in intestine.at the end of infusion (hour 5)

Secondary

MeasureTime frame
Comparison of protein expression pattern and glutathione synthesis.at the end of infusion (hour 5)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026